Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Complement System01:27

Complement System

9.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.7K
Humoral Immune Responses01:36

Humoral Immune Responses

83.3K
Overview
83.3K
Antibody Actions01:26

Antibody Actions

2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

14.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
14.0K
Rh Blood Group01:19

Rh Blood Group

2.7K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Death following high-dose AAV9 gene therapy in a patient with advanced SMA-PME.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Association of Complement Genetics with Outcomes in IgA Nephropathy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Thrombotic Microangiopathy, Cryoglobulinemia, and Acute Kidney Injury in Patients With Monoclonal Gammopathy: A Case Series.

American journal of hematology·2026
Same author

Implementing universal firearm injury prevention interventions across pediatric trauma centers: A type II hybrid effectiveness-implementation study protocol.

Journal of pediatric surgery·2026
Same author

Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases.

EBioMedicine·2026
Same author

Meningococcal Serogroup Y Meningitis Reveals Inborn Factor B Deficiency.

European journal of immunology·2026

相关实验视频

Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

在血液溶解性疾病中的补充向疗法.

Anna Duval1, Julia Roquigny2, Véronique Frémeaux-Bacchi3

  • 1Department of Nephrology, Dialysis and Transplantation, Strasbourg University Hospitals, Strasbourg, France; INSERM UMR_1109 Molecular Immuno Rheumatology, Strasbourg University, France.

Current opinion in immunology
|October 30, 2025
PubMed
概括

补充抑制疗法正在推进溶血性疾病的治疗. 较新的药物向早期补充通路,提供个性化,有效的口服或皮下选择,超出C5抑制.

更多相关视频

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.1K
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
06:27

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis

Published on: January 2, 2017

18.7K

相关实验视频

Last Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.1K
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
06:27

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis

Published on: January 2, 2017

18.7K

科学领域:

  • 血液学 血液学 血液学
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 补充抑制已经改变了溶血性疾病的管理.
  • 传统疗法集中在终端补充成分5 (C5) 抑制上.
  • 新兴的策略针对早期的补充级联组件.

研究的目的:

  • 审查最近的补充抑制对血液溶解性疾病的进展.
  • 突出针对近位补体通路的新型治疗剂.
  • 讨论基于疾病特征的个性化治疗方法.

主要方法:

  • 审查最近的临床研究和补充抑制的治疗发展.
  • 对针对C3,B因子和D因子的新型补剂抑制剂的分析.
  • 评估治疗的疗效在晚间性血红蛋白尿症,非典型的血溶性尿素综合征,和冷凝固素疾病.

主要成果:

  • 新的药物如佩格塞塔科普兰 (pegcetacoplan),伊普塔科潘 (iptacopan) 和达尼科潘 (danicopan) 向靠近补体通路.
  • 这些药物有效地管理了血管内和血管外血解.
  • 现在有口服和皮下注射的选择.
  • 苏提利马布通过抑制经典途径,在冷凝素疾病中表现出有效性.

结论:

  • 补剂抑制剂的领域已经显著扩大,提供近位和终端途径向.
  • 创新使得血溶性疾病的个性化治疗策略成为可能.
  • 特定途径的干预措施优化了患者的护理和结果.